Primary Myelofibrosis
Showing 76 - 100 of >10,000
Primary Myelofibrosis Trial (Pacritinib)
Withdrawn
- Primary Myelofibrosis
- Pacritinib
- (no location specified)
May 3, 2021
Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia Trial in United States (Panobinostat)
Terminated
- Primary Myelofibrosis
- +2 more
-
Scottsdale, Arizona
- +8 more
Jul 9, 2021
Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],
Recruiting
- Myeloproliferative Neoplasm
- +5 more
- Apixaban 2.5 MG Oral Tablet [ELIQUIS]
- Aspirin 81 mg
-
Ottawa, Ontario, CanadaThe Ottawa Hospital
Apr 19, 2022
Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis Trial in Worldwide
Completed
- Idiopathic Myelofibrosis
- +2 more
-
Paris, France
- +9 more
Jun 22, 2021
Myelofibrosis, Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis Trial in Hangzhou (Jaktinib HCl tablets)
Recruiting
- Myelofibrosis
- +3 more
- Jaktinib hydrochloride tablets
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Jun 11, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Duarte (drug, procedure, other)
Recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis Trial in Worldwide
Completed
- Primary Myelofibrosis
- +2 more
-
Phoenix, Arizona
- +61 more
May 5, 2022
Moderate and High Risk Myelofibrosis Trial in China (TQ05105 tablets, Hydroxycarbamide tablets)
Recruiting
- Moderate and High Risk Myelofibrosis
- TQ05105 tablets
- Hydroxycarbamide tablets
-
Beijing, Beijing, China
- +3 more
Nov 23, 2021
Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis Trial in Worldwide (RO7490677,
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Duarte (procedure, drug, other)
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 2, 2021
Myelofibrosis (MF) Trial in Korea, Republic of, South Africa, United States (Mivebresib, Navitoclax, Ruxolitinib)
Active, not recruiting
- Myelofibrosis (MF)
- Mivebresib
- +2 more
-
Stony Brook, New York
- +6 more
Mar 23, 2022
Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Boston, Bronx, New
Completed
- Chronic Phase Myelofibrosis
- +3 more
-
Boston, Massachusetts
- +2 more
May 27, 2021
Primary Myelofibrosis, Secondary Myelofibrosis, PMF Trial in Germany (INCB018424/CC-4047)
Active, not recruiting
- Primary Myelofibrosis
- +5 more
-
Aachen, Germany
- +16 more
Sep 28, 2021
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera
Completed
- Adherence, Patient
- Adherence, Treatment
-
Cosenza, Calabria, Italy
- +27 more
Oct 11, 2023
Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States
Recruiting
- Accelerated/Blast-phase Myeloproliferative Neoplasm
- +2 more
-
Scottsdale, Arizona
- +10 more
May 9, 2022
Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis Trial in Miami, Chicago, Rochester (Alisertib, Laboratory
Active, not recruiting
- Acute Megakaryoblastic Leukemia
- +2 more
- Alisertib
- +2 more
-
Miami, Florida
- +2 more
May 4, 2021
Thrombocythemia, Essential, Primary Myelofibrosis Trial in Worldwide (Bomedemstat)
Enrolling by invitation
- Thrombocythemia, Essential
- Primary Myelofibrosis
-
Miami, Florida
- +18 more
Jan 30, 2023
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary
Recruiting
- Myelofibrosis Transformation in Essential Thrombocythemia
- +2 more
- Elotuzumab
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Feb 17, 2021